Dabrafenib

• CAT Number: I006367
• CAS Number: 1195765-45-7 (free base)
• Molecular Formula: C23H20F3N5O2S2
• Molecular Weight: 519.56
• Purity: ≥95%
• Synonyms: N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°C for short term or -20 °C for long term
• IUPAC Name: N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide
• InChI: InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)
• InChIKey: BFSMGDJOXZAERB-UHFFFAOYSA-N
• SMILES: CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F

Dabrafenib(CAT: I006367) is a potent and selective inhibitor of BRAF kinase, specifically targeting the BRAF V600E mutation, a key driver in various cancers such as melanoma, thyroid cancer, and non-small cell lung cancer (NSCLC). By inhibiting mutated BRAF, Dabrafenib disrupts the MAPK/ERK signaling pathway, reducing cell proliferation and promoting apoptosis in tumor cells. Its high specificity minimizes off-target effects, making it a critical tool in cancer research. Dabrafenib is widely used to investigate oncogenic BRAF-driven pathways, resistance mechanisms, and combination therapies, advancing the development of targeted treatments for cancers harboring BRAF mutations.